The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...
One significant advancement in endometrial cancer treatment is the combination of lenvatinib, a targeted therapy, with pembrolizumab, an immunotherapy. A recent phase 3 trial demonstrated that ...
GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...
IFLScience on MSN6d
New Breast Cancer Drug Kills Mouse Tumors In Single DoseMore testing is needed, but if the same results are seen in humans, it could transform treatment of the disease.
Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...
GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...
GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...
European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback